← Back to Search

Other

MBX 2109 (Part A) for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by MBX Biosciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Body mass index between 20.0 and 32.0 kg/m2, inclusive.
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through day 40 (part a) or day 60 (part b)
Awards & highlights

Study Summary

This trial is evaluating the safety and tolerability of a new drug called MBX 2109 given as a shot under the skin. The study will also look at how well the drug is absorbed and how it affects the body.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
Your body mass index (BMI) is between 20 and 32, which is considered a healthy range.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through day 40 (part a) or day 60 (part b)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through day 40 (part a) or day 60 (part b) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Measures
Secondary outcome measures
Measures 1
Measures 2

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: MBX 2109 (Part B)Experimental Treatment1 Intervention
Repeated ascending SC doses
Group II: MBX 2109 (Part A)Experimental Treatment1 Intervention
Single ascending SC doses
Group III: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MBX 2109 (Part A)
2021
Completed Phase 1
~80
MBX 2109 (Part B)
2021
Completed Phase 1
~80

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

MBX BiosciencesLead Sponsor
1 Previous Clinical Trials
84 Total Patients Enrolled
Mary Jane Geiger, MD, PhDStudy DirectorMBX Biosciences

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has MBX 2109 (Part A) obtained regulatory approval from the FDA?

"Due to limited data supporting both safety and efficacy, MBX 2109 (Part A) was ranked a 1 on our team's scale of risk."

Answered by AI

How many participants are currently included in this investigation?

"Affirmative. According to the details on clinicaltrials.gov, this research project was initially posted in November 2021 and has since been updated in October 2022. 80 participants are required from two distinct hospitals for the trial's completion."

Answered by AI

For what kind of participant is this experiment best suited?

"This medical trial seeks 80 adults aged 21-60 with healthy subject status. The other requirements include a BMI between 20 and 32, no clinically relevant findings from physical exams or lab tests, as well as being of non-childbearing potential."

Answered by AI

Is there an age limit to be eligible for engaging in this research?

"To be eligible for this research, applicants must fall between 21 to 60 years old. There are 50 trials available for minors and 373 studies that focus on individuals over 65."

Answered by AI

Are there any current vacancies available in this trial?

"Affirmative. The details shared on clinicaltrials.gov denote that recruitment for this research experiment is ongoing. This project, which was first posted in November 10th 2021, requires 80 volunteers from 2 locations to take part."

Answered by AI

Who else is applying?

What state do they live in?
Illinois
Florida
California
How old are they?
18 - 65
What site did they apply to?
Labcorp Drug Development: Clinical Research Unit
What portion of applicants met pre-screening criteria?
Met criteria

How responsive is this trial?

Average response time
  • < 1 Day
Typically responds via
Phone Call
Most responsive sites:
  1. Labcorp Drug Development: Clinical Research Unit: < 24 hours
~23 spots leftby Mar 2025